Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

2025-521488-11-00

EU Clinical Trials Information System

Trial ID
T-ctis-2025-521488-11-00
Registry
EU Clinical Trials Information System
CTIS number
2025-521488-11-00
Asset
psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg)
Sponsor, as registered
ARQ National Psychotrauma Centrum
Phase
Therapeutic exploratory (Phase II)
Indication
Posttraumatic stress disorder
Status
Authorised
Primary completion
CTIS does not publish one.
Member states concerned
Netherlands
Sites
1

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-09-08

Notes on the record

Decision date 2026-06-22, record published 2026-06-23, 67 days before the ClinicalTrials.gov record NCT07792538 first posted on 2026-08-28. Products PEX010 Psilocybin Capsules 25 mg and 5 mg; totalNumberEnrolled 12; sponsor type Patient organisation/association, Non-Commercial. Read from the CTIS public API retrieve endpoint. countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded in this table; see data/decisions.csv.

Company

Through psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg): ARQ Centrum'45

Cited in

Issues quoting 2025-521488-11-00 in their own text.